Wockhardt has received shareholders’ approval to raise funds of upto Rs 1,200 crore by issuance and allotment of secured/un-secured redeemable Non-Convertible Debentures (NCDs) on private placement basis in one or more tranches.
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
